Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1993 | 1 |
2010 | 1 |
2011 | 1 |
2012 | 3 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network.
Clin Infect Dis. 2012 May;54 Suppl 4:S261-5. doi: 10.1093/cid/cir995.
Clin Infect Dis. 2012.
PMID: 22544185
Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Stevens WS, Rinke de Wit TF, Schuurman R; PharmAccess African Studies to Evaluate Resistance (PASER).
Hamers RL, et al.
Clin Infect Dis. 2012 Jun;54(11):1660-9. doi: 10.1093/cid/cis254. Epub 2012 Apr 3.
Clin Infect Dis. 2012.
PMID: 22474222
Item in Clipboard
HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.
Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes ME, Wellington M, Osibogun A, Sigaloff KC, Nankya I, Schuurman R, Wit FW, Stevens WS, van Vugt M, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER).
Hamers RL, et al.
Lancet Infect Dis. 2011 Oct;11(10):750-9. doi: 10.1016/S1473-3099(11)70149-9. Epub 2011 Jul 27.
Lancet Infect Dis. 2011.
PMID: 21802367
Item in Clipboard
Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific.
Hamers RL, Oyomopito R, Kityo C, Phanuphak P, Siwale M, Sungkanuparph S, Conradie F, Kumarasamy N, Botes ME, Sirisanthana T, Abdallah S, Li PC, Ngorima N, Kantipong P, Osibogun A, Lee CK, Stevens WS, Kamarulzaman A, Derdelinckx I, Chen YM, Schuurman R, van Vugt M, Rinke de Wit TF; PharmAccess African PASER and TREAT Asia Studies to Evaluate Resistance.
Hamers RL, et al.
Int J Epidemiol. 2012 Feb;41(1):43-54. doi: 10.1093/ije/dyq192. Epub 2010 Nov 10.
Int J Epidemiol. 2012.
PMID: 21071386
Free PMC article.
No abstract available.
Item in Clipboard
HLA-Dr-expressing CD8bright cells are only temporarily present in the circulation during subcutaneous recombinant interleukin-2 therapy in renal cell carcinoma patients.
Janssen RA, Buter J, Straatsma E, Heijn AA, Sleijfer DT, de Vries EG, Mulder NH, The TH, de Leij L.
Janssen RA, et al. Among authors: straatsma e.
Cancer Immunol Immunother. 1993;36(3):198-204. doi: 10.1007/BF01741092.
Cancer Immunol Immunother. 1993.
PMID: 8439981
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite